Affibody AB Competitors, Revenue, Alternatives and Pricing

Claim your profile


Solna, SWE Sweden
Total Funding:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Affibody AB's estimated annual revenue is currently $15.3M per year.(?)
  • Affibody AB's estimated revenue per employee is $155,000

Employee Data

  • Affibody AB has 99 Employees.(?)
  • Affibody AB grew their employee count by 16% last year.
  • Affibody AB currently has 1 job openings.

Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod, for outlicensing. The company is currently developing four proprietary programs. The first three are therapeutic programs that targets liver diseases, autoimmune diseases, and psoriasis respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody also has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, Nordic Nanovector, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.